367 related articles for article (PubMed ID: 32814115)
1. Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress.
Neganova ME; Klochkov SG; Aleksandrova YR; Aliev G
Semin Cancer Biol; 2022 Aug; 83():452-471. PubMed ID: 32814115
[TBL] [Abstract][Full Text] [Related]
2. Advances in Epigenetic Cancer Therapeutics.
Hillyar C; Rallis KS; Varghese J
Cureus; 2020 Nov; 12(11):e11725. PubMed ID: 33391954
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
[TBL] [Abstract][Full Text] [Related]
5. Histone modification therapy of cancer.
Biancotto C; Frigè G; Minucci S
Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery.
Ganesan A; Nolan L; Crabb SJ; Packham G
Curr Cancer Drug Targets; 2009 Dec; 9(8):963-81. PubMed ID: 20025605
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Modulators as Therapeutic Agents in Cancer.
Patnaik E; Madu C; Lu Y
Int J Mol Sci; 2023 Oct; 24(19):. PubMed ID: 37834411
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Targets and their Inhibitors in Cancer Therapy.
Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation of gene expression as an anticancer drug target.
Ferguson LR; Tatham AL; Lin Z; Denny WA
Curr Cancer Drug Targets; 2011 Feb; 11(2):199-212. PubMed ID: 21158714
[TBL] [Abstract][Full Text] [Related]
10. Targeting epigenetic regulation for cancer therapy using small molecule inhibitors.
Kumar A; Emdad L; Fisher PB; Das SK
Adv Cancer Res; 2023; 158():73-161. PubMed ID: 36990539
[TBL] [Abstract][Full Text] [Related]
11. Epigenetics in cancer: targeting chromatin modifications.
Ellis L; Atadja PW; Johnstone RW
Mol Cancer Ther; 2009 Jun; 8(6):1409-20. PubMed ID: 19509247
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy.
Zahnow CA; Topper M; Stone M; Murray-Stewart T; Li H; Baylin SB; Casero RA
Adv Cancer Res; 2016; 130():55-111. PubMed ID: 27037751
[TBL] [Abstract][Full Text] [Related]
14. Targeting Chromatin Remodeling for Cancer Therapy.
Kaur J; Daoud A; Eblen ST
Curr Mol Pharmacol; 2019; 12(3):215-229. PubMed ID: 30767757
[TBL] [Abstract][Full Text] [Related]
15. Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy.
Morera L; Lübbert M; Jung M
Clin Epigenetics; 2016; 8():57. PubMed ID: 27222667
[TBL] [Abstract][Full Text] [Related]
16. Luteolin Causes 5'CpG Demethylation of the Promoters of TSGs and Modulates the Aberrant Histone Modifications, Restoring the Expression of TSGs in Human Cancer Cells.
Pramodh S; Raina R; Hussain A; Bagabir SA; Haque S; Raza ST; Ajmal MR; Behl S; Bhagavatula D
Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409426
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V; Gozzini A; Ferrari G
Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
[TBL] [Abstract][Full Text] [Related]
18. Epigenetically Active Drugs Inhibiting DNA Methylation and Histone Deacetylation.
Chistiakov DA; Myasoedova VA; Orekhov AN; Bobryshev YV
Curr Pharm Des; 2017; 23(8):1167-1174. PubMed ID: 27774908
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic inhibitors and their role in cancer therapy.
Abdelaziz N; Therachiyil L; Sadida HQ; Ali AM; Khan OS; Singh M; Khan AQ; Akil ASA; Bhat AA; Uddin S
Int Rev Cell Mol Biol; 2023; 380():211-251. PubMed ID: 37657859
[TBL] [Abstract][Full Text] [Related]
20. Molecular targets for epigenetic therapy of cancer.
Humeniuk R; Mishra PJ; Bertino JR; Banerjee D
Curr Pharm Biotechnol; 2009 Feb; 10(2):161-5. PubMed ID: 19199948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
